Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on June 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on May 30th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
- Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
- Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
- Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
- Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
- Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
- Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
- Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
- Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
- Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.
Pfizer Price Performance
NYSE:PFE traded up $0.18 during mid-day trading on Wednesday, hitting $25.32. The company's stock had a trading volume of 42,017,222 shares, compared to its average volume of 41,933,765. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $143.98 billion, a price-to-earnings ratio of 18.35, a P/E/G ratio of 0.88 and a beta of 0.58. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock has a fifty day moving average of $24.07 and a 200-day moving average of $24.71.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.79%. Pfizer's dividend payout ratio is currently 124.64%.
Wall Street Analyst Weigh In
PFE has been the subject of a number of recent research reports. Redburn Atlantic cut their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Leerink Partners decreased their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Bank of America boosted their price objective on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, TD Cowen decreased their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $28.55.
View Our Latest Report on Pfizer
Institutional Investors Weigh In On Pfizer
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tallon Kerry Patrick bought a new stake in Pfizer during the 4th quarter valued at approximately $509,000. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Sargent Investment Group LLC boosted its position in shares of Pfizer by 7.1% during the fourth quarter. Sargent Investment Group LLC now owns 8,093 shares of the biopharmaceutical company's stock worth $217,000 after buying an additional 536 shares during the period. Finally, Stratos Investment Management LLC boosted its position in Pfizer by 36.9% in the 4th quarter. Stratos Investment Management LLC now owns 20,430 shares of the biopharmaceutical company's stock valued at $542,000 after buying an additional 5,502 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
